表紙
市場調查報告書

醫藥品分析:MenABCW-135Y

MenABCW-135Y

出版商 Datamonitor Healthcare 商品編碼 912151
出版日期 內容資訊 英文 12 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
醫藥品分析:MenABCW-135Y MenABCW-135Y
出版日期: 2019年09月03日內容資訊: 英文 12 Pages
簡介

GlaxoSmithKline所開發的MenABCW-135Y,是腦膜炎用5價 (A,B,C,W-135,Y) 結合疫苗之一。現在第二階段臨床實驗完成,預計2019年第三階段臨床實驗也將結束,2022年取得美國、歐洲的認證。

本報告以現在開發中的腦膜炎疫苗MenABCW-135Y為焦點,產品的概要和目前臨床實驗趨勢,未來認證、上市預測,市場規模、佔有率趨勢預測,產品市場SWOT分析等資訊彙整,為您概述為以下內容。

目錄

概要

  • 醫藥品概要
  • 產品簡介
  • MenABCW-135Y:腦膜炎疫苗
目錄
Product Code: DMKC0157288

Drug Overview

GlaxoSmithKline's MenABCW-135Y is a pentavalent meningococcal conjugate vaccine for the A, B, C, W-135, and Y meningococcal strains. With all of the vaccine's announced Phase II trials now complete, Datamonitor Healthcare expects that Phase III trials could start by the end of 2019, and forecasts US and EU approvals in adolescents and adults to occur as early as 2022.

Following its anticipated approvals in the US and EU in 2022, MenABCW-135Y is expected to replace marketed vaccines Bexsero (multicomponent meningococcal serogroup B vaccine; GlaxoSmithKline) and Menveo (quadrivalent oligosaccharide diphtheria CRM-197 conjugate vaccine; GlaxoSmithKline) on the market if it is able to demonstrate non-inferior immunogenicity in persons aged ≥10 years. MenABCW-135Y's broad serotype coverage positions it well to replace Bexsero and Menveo in markets where both of the aforementioned products are reimbursed, as it would be the first meningococcal vaccine on the market to cover all of the major disease-causing serotypes: A, B, C, W, and Y. Thus far, MenABCW-135Y has demonstrated non-inferior immunogenicity to Menveo in Phase II trials, but it will also need to demonstrate non-inferior immunogenicity against serotype B when compared to Bexsero if it hopes to successfully cannibalize Bexsero's and Menveo's market shares.

TABLE OF CONTENTS

OVERVIEW

  • Drug Overview
  • Product Profiles
  • MenABCW-135Y : Meningococcal vaccines

LIST OF TABLES

  • Table 1: MenABCW-135Y drug profile
  • Table 2: Late-phase trials of MenABCW-135Y for meningococcal vaccination
  • Table 3: MenABCW-135Y for meningococcal disease - SWOT analysis
Back to Top